Clinical Trial

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Name: Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies — clinical trial record (NCT07511972)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Withdrawn Phase 2

View on ClinicalTrials.gov →

Why the trial stopped

Study terminated by Sponsor

Summary

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Trial Details

NCT Number	NCT07511972
Lead Sponsor	NGM Biopharmaceuticals, Inc
Conditions	CRC
Start Date	2023-11-14
Primary Completion	2024-12-31 (estimated)
Study Completion	2025-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-06